Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
Joseph P. Slattery, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2024.
Summary
- On April 1, 2024, Joseph P. Slattery, a director of Replimune Group, Inc., acquired stock options.
- The options grant the right to buy 32,000 shares of common stock at an exercise price of $7.73.
- The options vest entirely on April 1, 2025, and expire on April 1, 2034.
- Following the transaction, Mr. Slattery directly owns options for 32,000 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option acquisition by a director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard disclosure of insider transactions, common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.
Stakeholder Impact
- The transaction could signal confidence in the company's future prospects from a director's perspective, potentially influencing shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: Director acquired stock options. |
| 04/01/2025 | Vesting date: Options vest entirely. |
| 04/01/2034 | Expiration date: Options expire. |
| 04/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.